NCT05952089View on ClinicalTrials.gov

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

March 15, 2024

Study Completion Date

March 19, 2024

Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
DRUG

Danicamtiv

Specified dose on specified days

DRUG

Midazolam

Specified dose on specified days

Trial Locations (5)

21215

Sinai Hospital Of Baltimore, Baltimore

32216

Jacksonville Center For Clinical Research, Jacksonville

33308

Holy Cross Hospital, Fort Lauderdale

34452

Nature Coast Clinical Research, Inverness

42303

Research Integrity LLC, Owensboro

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05952089 - A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure | Biotech Hunter | Biotech Hunter